Navigation Links
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Date:6/26/2009

n adverse drug reaction reported from clinical trials through week 16 was upper respiratory tract infection (7.2 percent of SIMPONI-treated patients compared with 5.8 percent in control-treated patients). In controlled Phase 3 trials through Week 16 in RA, PsA and AS, 5.8 percent of SIMPONI treated patients had injection site reactions compared with 2.2 percent in control-treated patients. The majority of the injection site reactions were mild and moderate, and the most frequent manifestation was injection site erythema.

For the Full U.S. Prescribing Information and Medication Guide, please visit www.SIMPONI.com.

About Centocor Ortho Biotech, Inc.

Centocor Ortho Biotech Inc. redefines the standard of care in immunology, nephrology, and oncology. The company was created when Ortho Biotech Inc. merged into Centocor, Inc., and Centocor, Inc. was renamed Centocor Ortho Biotech Inc. Built upon a pioneering history, Centocor Ortho Biotech Inc. harnesses innovations in large-molecule and small-molecule research to create important new therapeutic options. Beyond its innovative medicines, Centocor Ortho Biotech is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates, and healthcare professionals have access to the latest treatment information, support services, and quality care. Centocor Ortho Biotech is a wholly-owned subsidiary of Johnson & Johnson.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Centocor Ortho Biotech Inc. and/or Johnson & Johnso
'/>"/>

SOURCE Schering-Plough Corporation; Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
2. Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
3. Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
4. Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System
5. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
6. Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
7. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
8. AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria
9. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
10. Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma
11. Pelleve Receives FDA Clearance for the Treatment of Mild to Moderate Facial Wrinkles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "12th ... and Production" report to their offering. ... of Biopharmaceutical Manufacturing Capacity and Production is the ... manufacturing organizations, current and projected future capacity and ...
(Date:8/28/2015)... Patterson Medical, formerly the medical business ... is now an independent company with today,s completion ... by Madison Dearborn Partners (MDP).  ... transition period before rebranding as the world,s leading ...  With the focused resources and expertise of MDP, ...
(Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Latanoprost Market, ... Developed by Pharmacia & Upjohn in 1995, latanoprost ... reduces intraocular pressure. As the first pressure- lowering ... name of Xalatan) entered China ...
Breaking Medicine Technology:12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3China Latanoprost Market Investigation Report 2015-2019 2
... Pharmaceutical,Inc.,s (OTC Bulletin Board: NURX) next-generation rexinoid agonist,NRX4204, ... tumors and,lowered the total tumor volume in mouse ... paper published in Clinical Cancer Research (2007;,Vol. 13, ... showed that NRX4204 caused marked tumor,regression in all ...
... provide best science available, BETHESDA, Md., March ... methodology for CNS clinical trials, United BioSource,Corporation (UBC) ... for,Data Quality. This Advisory Board was established to ... quality and outcomes in CNS trials that,rely on ...
Cached Medicine Technology:Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports 2Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports 3UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials 2UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials 3
(Date:8/30/2015)... ... August 31, 2015 , ... ... third of tax receipts, issues that are critically important to them are often ... attorneys and lobbyists monitoring proposed legislation and changing tax and regulatory policies. Smaller ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... announce that Partner Daniel M. Kotin was recently elected to membership in the ... the highest degree of peer recognition and outstanding professionalism. , ABOTA is ...
(Date:8/30/2015)... ... 2015 , ... Natural Rest contains a unique mixture of vitamins and herbs ... which help to improve mood disorders and anxiety. Like all other Creative Medical Health ... field of regenerative medicine conducted by Dr. Amit Patel of the University of Utah, ...
(Date:8/29/2015)... ... , ... Rio Salado College President Chris Bustamante announced on Aug. ... Strategic Initiatives and Information Services. O’Shea, who has served Rio Salado for the last ... impact through innovative technologies and strategies. , “I am very proud to be able ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... scrotal support and protection against dribbled urine and sweat. "In order to prevent ... N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support for ...
Breaking Medicine News(10 mins):Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 2Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 3Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 4Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 2Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 3Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2
... for its high standards in nursing quality, today announced the ... excellence. The honor is determined by the American Nurses ... best in patient care. The ANCC notified Northwestern Memorial ... status sets our hospital apart and places us amongst a ...
... conducting basic research on ion channels have demonstrated a ... pain., Targeting these ion channels pharmacologically would offer effective ... painkilling drugs, according to their paper, published in a ... is the most common symptom of injuries and diseases, ...
... -- Among people with rheumatoid arthritis, 11 percent of those ... had been seeing one for quite a while. In ... other medical words related to rheumatoid arthritis, such as "osteoporosis" ... noted that previous findings have suggested that low levels of ...
... stop unwanted intruders, the skin serves as a barrier protecting ... microbes people come in contact with every day. In patients ... skin disease, the skin barrier is leaky, allowing intruders ... be sensed by the skin and subsequently wreak havoc on ...
... By Steven Reinberg HealthDay Reporter , ... percent of American adults say they had difficult childhoods ... who were absent due to separation or divorce, federal ... said that while growing up they underwent five or ...
... Social Graph app, researchers in the ADVANCE project at ... to help women scientists and engineers supercharge their careers. ... balance sheets. They,re webs of human interaction," said Nancy ... Technology and the ADVANCE project leader. "The complex structure ...
Cached Medicine News:Health News:Northwestern Memorial maintains top status in nursing hospital renewed for Nurse Magnet® 2Health News:Ion channel responsible for pain identified by UB neuroscientists 2Health News:Patient Literacy Problems Can Hinder Rheumatoid Arthritis Care 2Health News:Study reveals major shift in how eczema develops 2Health News:Study reveals major shift in how eczema develops 3Health News:Majority of U.S. Adults Had Troubled Childhoods: CDC 2Health News:Majority of U.S. Adults Had Troubled Childhoods: CDC 3Health News:Mapping faculty social networks helps female faculty move ahead at NJIT 2Health News:Mapping faculty social networks helps female faculty move ahead at NJIT 3
... this is the universal lithotripter for ... urinary and biliary treatment. The system ... with other applications including cystoscopy, ureteronoscopy, ... system comprises the height adjustable urologist' ...
... This therapeutic system ... the patient in mind. ... surgery and ongoing therapy, ... low-risk and effective therapy. ...
... Reach a new dimension! That of the ... unequalled performance and ease of use. Enjoy ... electroconductive shock wave technology coupled with the ... system. Manage the patient treatment, X-ray and ...
... The MINILITH SL1 developed by STORZ ... of extensive experience in the field of ... of the specific requirements to be met ... therapy, as has been outlined above. The ...
Medicine Products: